gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Melanoma antigen family A, 2

MAGE-2
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. This gene has two identical copies at different loci. Alternatively spliced transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: MAGE-1, MAGE-3, POLYMERASE, MAGE-4, CAN
Papers on MAGE-2
Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization.
Tokura et al., Hamamatsu, Japan. In J Dermatol Sci, 2014
METHODS: We performed PPI in 59 patients undergoing advanced MM with Melan-A, tyrosinase, MAGE-2, MAGE-3 and gp-100 peptides based on HLA typing in individuals.
Proteins differentially expressed in human beta-cells-enriched pancreatic islet cultures and human insulinomas.
Sogayar et al., São Paulo, Brazil. In Mol Cell Endocrinol, 2014
In contrast, almost all proteins more abundant in insulinoma cells, such as MAGE2, were first described here and could be related to cell survival and resistance to chemotherapy.
MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
GeneRIF
Schneider et al., Trieste, Italy. In Cell Death Differ, 2012
MageA2 interferes with p53 acetylation at PML-nuclear bodies (NBs) and with PMLIV-dependent activation of p53.
MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases.
GeneRIF
Jeon et al., Taegu, South Korea. In Oncol Rep, 2012
Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells.
The role of MAGEA2 in head and neck cancer.
GeneRIF
Califano et al., Baltimore, United States. In Arch Otolaryngol Head Neck Surg, 2011
These data suggest that MAGEA2 is differentially expressed in HNSCC and functions, in part, through the p53 pathway by increasing cellular proliferation and abrogating cell cycle arrest.
Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Sarobe et al., Pamplona, Spain. In Scand J Immunol, 2009
In this study, with the aim of inducing multiepitopic responses against several common tumour antigens, we have designed a minigene construct encoding four human leucocyte antigen (HLA)-A2-restricted epitopes belonging to tumour antigens CEA (CEA-691 and CEA-571), MAGE2 (MAGE2-157) and MAGE3 (MAGE3-112), as well as the universal PADRE epitope recognized by T helper lymphocytes.
Detection of isolated tumour cells in the blood and bone marrow of patients with gastric cancer by combined sorting, isolation and determination of MAGE-1, -2 mRNA expression.
Zembala et al., Kraków, Poland. In Oncol Rep, 2008
The MAGE-2 mRNA expression was observed in 40 and 58% of samples, respectively.
Expression of melanoma-associated antigens in oral squamous cell carcinoma.
GeneRIF
Nkenke et al., Erlangen, Germany. In J Oral Pathol Med, 2008
Multiple simultaneous detection of MAGE-A [subtypes] more specific and sensitive than detection of single MAGE-A antigen for the diagnostic and prognostic evaluation of oral squamous cell carcinoma
Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.
Yannelli et al., Lexington, United States. In Lung Cancer, 2007
Autologous DCs were pulsed with apoptotic bodies derived from an allogeneic NSCLC cell line that over-expresses Her2/neu, CEA, WT1, Mage2, and survivin.
Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
GeneRIF
Schwarzenbach et al., Hamburg, Germany. In Mol Cancer Res, 2007
These data show, for the first time, the involvement of methyl-CpG binding domain proteins in the regulation of the MAGE-A genes.
Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy.
Wiltfang et al., Erlangen, Germany. In Int J Oncol, 2005
The expression pattern of subtypes was heterogeneous: 62% of the tumor patients were positive for MAGE-3, 57% for MAGE-4, 48% for MAGE-6, 43% for MAGE-1, 38% for MAGE-2 and 24% for MAGE-5.
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells.
Yamaguchi et al., Shizuoka, Japan. In J Transl Med, 2005
After pulsing with a cocktail of 5 melanoma-associated synthetic peptides (gp100, tyrosinase, MAGE-2, MAGE-3 and MART-1 or MAGE-1) restricted to HLA-A2 or A24 and KLH, cells were cryopreserved until used.
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Wallwiener et al., Tübingen, Germany. In Cancer Immunol Immunother, 2005
KS breast cancer cells were demonstrated to express already known TAAs such as CEA, MUC-1, MAGE-1, MAGE-2, and MAGE-3.
Autologous dendritic cell vaccines for non-small-cell lung cancer.
Impact
Yannelli et al., Lexington, United States. In J Clin Oncol, 2004
METHODS: DC vaccines were generated from CD14+ precursors, pulsed with apoptotic bodies of an allogeneic NSCLC cell line that overexpressed Her2/neu, CEA, WT1, Mage2, and survivin.
Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Yamaguchi et al., Tokyo, Japan. In Anticancer Res, 2004
In this study, we investigated the specific CTL-inducing activity of 5 HLA-A*2402-restricted peptides derived from gp100, tyrosinase, MAGE1, MAGE2 and MAGE3.
Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Thielemans et al., Brussels, Belgium. In J Immunol, 2004
Interestingly, this new tumor-specific antigenic peptide corresponds to position 212-220 of MAGE-2, -3, -6, and -12.
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.
Seiden et al., Boston, United States. In Clin Cancer Res, 2003
Northern analysis demonstrates overexpression of MAGE2 but not Centrin 2. Extension of this analysis to other neighboring and non-neighboring representative cancer testis antigens reveals overexpression of MAGE3, MAGE6, MAGE11, and MAGE12, as well as GAGE-2, GAGE-4, GAGE-5, GAGE-6, and GAGE-7 (clustered on Xp11) in SKOV-3(TR), as compared with SKOV-3.
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Vitale et al., Italy. In J Clin Endocrinol Metab, 2003
SSX 2 was present only in one tissue, whereas BAGE, GAGE 1-6, MAGE-1, MAGE-2, MAGE-3, and SSX 1-5 were detected in two to five samples.
Molecular cloning and sequencing of feline melanoma antigen 2 (fMAGE-2) obtained from a lymphoma cell line.
Onishi et al., Yamaguchi, Japan. In Tissue Antigens, 2002
We hereby report the cloning and sequencing of MAGE cDNA clone, called feline MAGE-2 (fMAGE-2), obtained from a lymphoma cell line.
[LC/MS research on the isomers of special melanoma antigen-encoding gene-2 epitope peptide induced by solvent].
Zou et al., Chongqing, China. In Se Pu, 2001
To study the influence of different solvent systems on the isomers of melanoma antigen-encoding gene-2(MAGE-2) epitope peptide synthesized by Marrifield's solid synthesis method, MAGE-2(171-179) epitope peptides were pre-treated using ethanol and methanol systems respectively, and then analysed by RP-HPLC/MS, with dimethyl-sulphoxide (DMSO) as control solvent.
share on facebooktweetadd +1mail to friends